Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) of the type that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (“[***]”) in this...Strategic Collaboration, Option and License Agreement • January 17th, 2025 • Odyssey Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of March 29, 2024 (the “Effective Date”) by and between JANSSEN PHARMACEUTICA NV, a corporation organized and existing under the laws of Belgium (“Janssen”), ODYSSEY THERAPEUTICS, INC., a corporation organized under the laws of Delaware (“Odyssey”). Janssen and Odyssey each may be referred to herein individually as a “Party” or collectively as the “Parties.”
Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) of the type that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (“[***]”) in this...Strategic Collaboration, Option and License Agreement • October 7th, 2024 • Odyssey Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of March 29, 2024 (the “Effective Date”) by and between JANSSEN PHARMACEUTICA NV, a corporation organized and existing under the laws of Belgium (“Janssen”), ODYSSEY THERAPEUTICS, INC., a corporation organized under the laws of Delaware (“Odyssey”). Janssen and Odyssey each may be referred to herein individually as a “Party” or collectively as the “Parties.”